🔵 RESEARCH
Reinforcement learning agent optimises POCUS capture for heart failure
Researchers describe a budget-constrained RL agent that personalises POCUS video acquisition for multi-task heart failure detection under bedside time and operator limits.
If validated in real ED workflows, time-aware acquisition AI favours streamlined POCUS devices for non-specialists over feature-rich carts — pressuring incumbent ultrasound OEMs to retool around emergency and primary care users.
International journal of computer assisted radiology and surgery · 2026-05-04
Read more →
🔵 RESEARCH
Sonire opens first US trial of ultrasound-guided HIFU for pancreatic cancer
Sonire Therapeutics initiated SUNRISE-II, a US feasibility study of anesthesia-free, ultrasound-guided HIFU therapy in pancreatic cancer.
A credible US foothold in HIFU for pancreatic disease would put Sonire in direct line of sight of EDAP and SonaCare, and could attract strategic interest from Philips or GE, who have complementary ultrasound platforms but no therapeutic offering here.
🔴 REGULATORY
Abbott wins FDA clearance and CE mark for AI-enabled imaging device
Abbott secured simultaneous FDA clearance and CE mark for an AI-enabled imaging device, joining a vascular portfolio that grew 9.5% on an organic basis.
Coordinated dual-region launches are becoming table stakes for large medtech: Abbott can defend vascular share against AI-first entrants while raising the regulatory bar for pure-play imaging startups still working through single-market submissions.
⚪ INDUSTRY
SimonMed rolls out AIRS Medical AI-enhanced MRI across national network
SimonMed deployed AIRS Medical's AI-enhanced MRI software across its national outpatient imaging network to accelerate scans and lift throughput.
A network-wide rollout at one of the largest outpatient chains validates enterprise AI MRI as a recurring-revenue play and pressures rival chains to follow. The signal to watch is published utilisation and throughput data, not the press release.
🩺 EDITOR’S TAKE — FOR CLINICIANS
Watch how AI is being scoped to specific bedside questions — heart failure triage on POCUS, MRI acceleration at SimonMed sites. The deployment story now matters more than the algorithm; ask vendors for utilisation and throughput data, not just AUC.
📊 EDITOR’S TAKE — FOR INVESTORS
Abbott's dual FDA/CE nod and SimonMed's network-wide AIRS rollout show incumbents and outpatient chains are operationalising imaging AI at scale, on the heels of Aidoc's $150M Series E. Capital is rewarding distribution and regulatory execution over novel models.
🏭 EDITOR’S TAKE — FOR INDUSTRY
OEMs face a widening split: Abbott extends AI into vascular hardware, AIRS rides a 200+ site chain, while Sonire pushes therapeutic ultrasound into pancreatic cancer. Health systems should expect imaging vendors to bundle AI, workflow, and now therapy under single contracts.